Nemtabrutinib plus rituximab for first-line mantle cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new combination of two drugs, nemtabrutinib (a targeted pill) and rituximab (an antibody infusion), for people with mantle cell lymphoma (MCL) who haven't had prior treatment. The goal is to see how well these drugs work together to control the lymphoma.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have mantle cell lymphoma (MCL) confirmed by a biopsy.
- You have not had any previous systemic cancer treatment (like chemotherapy) for MCL.
- You are 18 years old or older.
- Your lymphoma can be seen on scans or measured by a doctor.
- Your blood counts and organ function (kidney, liver) are within acceptable limits.
- You are willing to use effective contraception to prevent pregnancy/impregnation.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three targeted drugs for mantle cell lymphoma that has come back or not responded to prior treatment. It aims to see if this new drug cocktail can work better than standard options.
This trial tests a combination of medicines to treat newly diagnosed high-risk mantle cell lymphoma (MCL). It may help shrink the lymphoma and improve outcomes, especially for people whose disease has higher-risk features.
This trial studies whether combining zanubrutinib and rituximab can better control indolent (slow-growing) mantle cell lymphoma. It aims to improve how long participants can stay without the lymphoma worsening.
This trial tests a combination of three drugs—obinutuzumab, zanubrutinib, and lenalidomide—as a first treatment for mantle cell lymphoma. The goal is to see if this approach is safe and effective for patients who have not had prior therapy.
This trial is testing a combination of chemotherapy and targeted drugs for people who have just been diagnosed with mantle cell lymphoma and haven't had any prior treatment (except short-term steroids or local radiation). It aims to see if adding newer targeted therapies can help keep the lymphoma in remission.
This study tests a combination of two drugs—glofitamab (given as an infusion) and pirtobrutinib (a pill)—for people with mantle cell lymphoma that has come back or not responded to previous treatment. The goal is to see if the combo works better than either drug alone.
Hear when a new Mantle Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.